Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

A class action lawsuit was filed against ARS Pharmaceuticals (SPRY) tied to its June 24, 2026 payer-access update for neffy, alleging impact on investor information. After the market closed on June 24, the stock fell $2.52 per share (down 23.9%) to close at $8.02 on June 25, 2026, following the statement that no new neffy commercial formulary additions or coverage decisions were issued for the July 1, 2026 cycle.

Analysis

The real signal here is not the lawsuit; it is that commercialization is still being gated by payer behavior, which is the key variable for any launch that depends on reimbursement rather than consumer pull-through. For a single-product small-cap, delayed formulary wins usually show up as a longer revenue ramp, heavier rebate burden, and more expensive customer acquisition, which can force gross-to-net pressure before the market has enough evidence to model peak sales confidently.

Second-order winners are the entrenched epinephrine franchises, especially VTRS, because payer inertia now has a fresh justification to stick with incumbents while the new entrant proves coverage and refill economics. The litigation itself can also suppress institutional sponsorship and keep short interest elevated, which matters more for a name like SPRY than the legal merits do; in small caps, an overhang often becomes a valuation discount long before it becomes a cash cost.

The consensus risk is overfocusing on the headline drawdown and underweighting the fact that this could still be a timing problem rather than a demand failure. What would falsify the bearish read is evidence of a meaningful payer-addition step-up in the next 1-2 formulary cycles, or prescription growth that offsets the missed July window; absent that, the stock likely trades as a slower-launch story for the next 1-3 months while the class action lingers for 6-18 months.

Key Decisions for Investors

• Short SPRY on any post-news bounce for a 1-3 month horizon; thesis is slower payer uptake and continued multiple compression. Cover if the company reports a clear formulary inflection or materially better net new script growth.
• Relative-value: long VTRS / short SPRY as a reimbursement-inertia pair trade. This is a cleaner way to express the view that incumbent epinephrine share is defended when payer access stalls; reassess if SPRY wins broad coverage.
• Do not buy SPRY into the current void unless you have confirmed July/August prescription acceleration and payer adds; the burden of proof has shifted to the company. If those data are missing, treat this as a watchlist name, not a conviction long.
• If SPRY listed options are liquid, consider a 1-2 month put spread rather than outright short exposure; the catalyst path is binary and borrow/financing risk can dominate in small caps. Falsify on any guidance raise tied to access wins.